Intellia Therapeutics (NTLA) Misses Q4 EPS by 15c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.09), $0.15 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $8.26 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Cintas beats estimates but stock edges lower
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance